Merck Drops Zocor Combo, But Keeps Going With Tredaptive
A brief mention in an SEC filing revealed that Merck has ceased the development of a combination cholesterol pill; the once hot ‘0524 program had languished in late-stages for several years.
A brief mention in an SEC filing revealed that Merck has ceased the development of a combination cholesterol pill; the once hot ‘0524 program had languished in late-stages for several years.